Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook
Ascendis Pharma A/S (NASDAQ:ASND) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Posts Tagged ‘NASDAQ:ASND’
Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects
Ascendis Pharma A/S (NASDAQ:ASND) is among the 12 best healthcare stocks to buy now.
12 Best Healthcare Stocks to Buy Now
Healthcare companies in the US are facing policy headwinds under President Donald Trump's Administration.
BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts.
10 Best 52-Week High Stocks to Buy According to Analysts
Volatility in the equity markets under President Donald Trump has already hit record highs. Amid the heightened volatility, US equities have also bounced back on optimism about...
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
12 Best Growth Stocks to Buy and Hold for the Long Term
The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment.
Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call Transcript May 1, 2025Ascendis Pharma A/S misses on earnings expectations.
10 Best Growth Stocks to Buy According to Billionaires
The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down...
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call Transcript February 12, 2025Ascendis Pharma A/S beats earnings expectations.
12 High Growth International Stocks to Invest in Now
On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Call. At this time all participants are in a listen-only mode.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2024 Earnings Call Transcript September 3, 2024Ascendis Pharma A/S misses on earnings expectations.
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
5 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 5 fastest growing health tech companies in the world.
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.
Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter 2023 investor letter.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Here’s Why Baron Health Care Fund Harvested Ascendis Pharma A/S (ASND)
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Q1 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Top 5 Growth Stocks in Biotech
Headquartered in Bermuda, Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company focusing on therapeutics for debilitating disorders.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Ascendis Pharma Full Year 2022 Financial Results Conference Call.
What Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice?
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here.
15 Most Advanced Countries in Europe
Over the course of recent human history, Europe has proven to be the bedrock of innovation.
Here’s the Reason for the Healthy Performance of Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter.
5 Best Guru Stocks To Buy Now
The Allstate Corporation (NYSE:ALL) is an Illinois-based company that provides property, casualty, and other insurance products in the United States and Canada.
15 Most Valuable Danish Companies in the World
In this article, we will take a look at 15 of the most valuable Danish companies in the world.
Here’s Why Ascendis Pharma A/S (ASND) Became a Detractor in Artisan Partners’ Portfolio
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter investor letter. A copy of the same can be downloaded here.
Artisan Partners ‘Remains Quite Optimistic’ in Ascendis Pharma (ASND)
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded...
Hedge Funds Are Dumping Ascendis Pharma A/S (ASND)
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital
In this piece, we will take a look at the top 5 pharmaceutical stocks to buy according to Peter Kolchinsky's RA Capital. If you want a comprehensive view of Dr.
Here’s Why Artisan Partners Increased its Ascendis Pharma (ASND) Position
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded...
Here is What Hedge Funds Think About Ascendis Pharma A/S (ASND)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change...
Is Ascendis Pharma A/S (ASND) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Should You Consider Investing in Ascendis Pharma (ASND)?
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded...
Is ASND Stock A Buy or Sell?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money ...
Free Stock Pick From Insider Monkey’s Monthly Newsletter
Our premium monthly newsletter costs $449 annually and features my personal stock picks.
Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Why Ascendis Pharma (ASND) Stock is a Compelling Investment Case
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here.
